CKDXF (Opthea) Total Receivables: $7.61 Mil (As of Jun. 2025)


What is Opthea Total Receivables?

Opthea CKDXF Total Receivables is $7.61 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Opthea's Total Receivables for the quarter that ended in Jun. 2025 was $7.61 Mil.

Opthea Total Receivables Historical Data

* Premium members only.

The historical data trend for Opthea's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea Total Receivables Chart

Opthea Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.54 6.56 6.56 11.82 7.61

Opthea Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.56 5.80 11.82 7.98 7.61

Opthea Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $7.61 Mil mean?
Opthea (CKDXF) has a Total Receivables of $7.61 Mil as of Jun. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Opthea and its competitors.
Is Opthea's Total Receivables too high?
Opthea's current Total Receivables is $7.61 Mil.
How does Opthea's Total Receivables compare to VRTX and REGN?
Opthea's Total Receivables of $7.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Opthea and its competitors. Opthea's current Total Receivables is $7.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (CKDXF) has a current Total Receivables of $7.61 Mil. The current Total Receivables is $7.61 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Opthea (CKDXF), the current Total Receivables is $7.61 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opthea Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.